Innovative mental health medicines

Albert Labs is different from the influx of biopharmaceutical companies

Real World Evidence

Albert Labs is working with the largest oncology centre in Europe to drive access to innovative mental health medicine and therapy. We are partnering with leading research experts, existing clinical infrastructure and patient pools, enabling Albert Labs to deliver therapies to patients in need. This route provides an immediate in market solution as well as reimbursement mechanisms to drive early and sustained revenues.
Fast Results

Using the accelerated RWE pathway will bring its psilocybin medicine KRN-101 to market in a fast and focused manner. RWE is an approved pathway to licensing medicines used for oncology treatments, Interestingly it was used successfully for the Covid-19 Vaccines, which were approved in record time by the MHRA (The UK regulatory body).
Low Cost, Risk Mitigated Strategy

Through a RWE strategy and utilising a natural compound with a history of safety, Albert Labs requires less capital expenditure than companies developing novel molecules or companies setting up clinic settings (e.g. Compass, Field Trip etc.). Randomised controlled trials can cost upwards of £½ billion and take 7-12 years. RWE offers a faster approach to achieving a licensed medicine.

Click here to access our investor documents

Albert Labs Value Proposition

From the influx of psychedelics deals

Large Addressable Market

Albert Labs first target, KRN-101 a solution for cancer-related anxiety boasts an immediate addressable market of 1.2million in the UK. With 50,000-100,000 new sufferers annually. Expanding this to Europe TAM is over 10 million with 500,000-700,000 new sufferers annually.
IP Protected Production

Albert Labs has a particular focus on natural psilocybin cultivation for which they have submitted a patent application. The patent will enable Albert Labs to scale their natural mycelium and produce consistent EU GMP psilocybin and the other synergistic activities to scale API dosage to meet the significant unmet demand.
Expert Team

Albert Labs has an experienced management team featuring renowned experts across multiple fields, including notable leaders in regulatory affairs and the commercialisation of medicines. Everyone has been impacted by mental health and our team is no exception. It is our collective mission to deliver a real solution to the mental health crisis.

Click here to access our investor documents

Interested in investing?

Fill out this form and we will email you with further instruction.

"*" indicates required fields

Name*

Email*

Phone*

Amount you want to invest?*

Currency

How did you hear about us?

Address

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Investing Eligibility*

This Subscription Agreement is to only be utilized by those persons resident in Canada or in an international jurisdiction other than the United States, and who are eligible to subscribe under one of the following prospectus exemptions:

Consent*

I consent to the Albert Labs privacy terms & conditions.

CAPTCHA

94245

*Upon completing this form one of the Albert Labs team will ensure you qualify for the investment.

Request a call-back from one of the Albert Labs’ Team.

Innovative mental health medicines

Albert Labs is different from the influx of biopharmaceutical companies

Real World Evidence

Fast Results

Low Cost, Risk Mitigated Strategy

Albert Labs Value Proposition

From the influx of psychedelics deals

Large Addressable Market

IP Protected Production

Expert Team

Interested in investing?

Hear more from our team

Latest Press Release

Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors